Last updated on February 2018

Research of Exenatide for Overweight/Obese PCOS Patients With IGR


Brief description of study

Compare the therapeutic effects of exenatide, metformin and their combination for 3 months on reproductive and metabolic improvements of overweight/obese PCOS patients with impaired glucose regulation.

Detailed Study Description

The investigators designed a randomized control trial to compare the therapeutic effects of exenatide, metformin and their combination for 3 months on reproductive and metabolic improvements of overweight/obese PCOS patients with impaired glucose regulation. The investigators plan to enroll 183 patients. Overweight and obese PCOS patients with newly diagnosed IGT; PCOS diagnosis is based on 2003 Rotterdam criteria. Overweight / obesity diagnostic criteria is based on WHO-WPR. IGR diagnostic criteria is based on 1998 WHO diagnostic criteria. Serious complications (cardiovascular events and recent significant liver, kidney or lung disease within 3 months); high blood pressure (>160/100mmHg); active infection; secondary diabetes; pregnancy; alcohol abuse; allergic to GLP-1 receptor agonist are excluded.

Then the investigators plan to randomly divide the 183 patients into 3 groups: exenatide group, metformin group, and combination group, with 61 samples for each group. Each group use specific treatment (showed as the group name) for 3 months. Before and after the intervention, the blood samples would be collected to glucose, insulin, lipid profile, sex hormones, blood chemistry for liver and kidney function etc., as well as the anthropometric measurement and image examinations.

The investigators will compare the data and finally identify the treatment effect of exenatide on PCOS patients.

Clinical Study Identifier: NCT03352869

Contact Investigators or Research Sites near you

Start Over

Wei Liu, MD

Renji Hospital Department of Endocrinology and Metabolism
Shanghai, China
  Connect »